Nav1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis
- PMID: 38172636
- PMCID: PMC10794151
- DOI: 10.1038/s41586-023-06888-7
Nav1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis
Abstract
Osteoarthritis (OA) is the most common joint disease. Currently there are no effective methods that simultaneously prevent joint degeneration and reduce pain1. Although limited evidence suggests the existence of voltage-gated sodium channels (VGSCs) in chondrocytes2, their expression and function in chondrocytes and in OA remain essentially unknown. Here we identify Nav1.7 as an OA-associated VGSC and demonstrate that human OA chondrocytes express functional Nav1.7 channels, with a density of 0.1 to 0.15 channels per µm2 and 350 to 525 channels per cell. Serial genetic ablation of Nav1.7 in multiple mouse models demonstrates that Nav1.7 expressed in dorsal root ganglia neurons is involved in pain, whereas Nav1.7 in chondrocytes regulates OA progression. Pharmacological blockade of Nav1.7 with selective or clinically used pan-Nav channel blockers significantly ameliorates the progression of structural joint damage, and reduces OA pain behaviour. Mechanistically, Nav1.7 blockers regulate intracellular Ca2+ signalling and the chondrocyte secretome, which in turn affects chondrocyte biology and OA progression. Identification of Nav1.7 as a novel chondrocyte-expressed, OA-associated channel uncovers a dual target for the development of disease-modifying and non-opioid pain relief treatment for OA.
© 2024. The Author(s).
Conflict of interest statement
S.G.W. has served as a paid advisor to OliPass, Navega Therapeutics, Sangamo Therapeutics, Chromocell, ThirdRock and Medtronics, and holds stock options in Navega. Compounds and constructs under development by these companies were not used or tested in this study. The remaining authors declare no competing interests.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig1_HTML.gif)
![formula image](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Figa_HTML.jpg)
![formula image](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Figb_HTML.jpg)
![formula image](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Figc_HTML.jpg)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig4_HTML.gif)
![Extended Data Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig5_ESM.gif)
![Extended Data Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig6_ESM.gif)
![Extended Data Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig7_ESM.gif)
![Extended Data Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig8_ESM.gif)
![Extended Data Fig. 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig9_ESM.gif)
![Extended Data Fig. 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig10_ESM.gif)
![Extended Data Fig. 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig11_ESM.gif)
![Extended Data Fig. 8](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig12_ESM.gif)
![Extended Data Fig. 9](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig13_ESM.gif)
![Extended Data Fig. 10](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig14_ESM.gif)
![Extended Data Fig. 11](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig15_ESM.gif)
![Extended Data Fig. 12](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10794151/bin/41586_2023_6888_Fig16_ESM.gif)
Similar articles
-
Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230.Biochem Biophys Res Commun. 2024 Aug 20;721:150126. doi: 10.1016/j.bbrc.2024.150126. Epub 2024 May 14. Biochem Biophys Res Commun. 2024. PMID: 38776832
-
Aberrant subchondral osteoblastic metabolism modifies NaV1.8 for osteoarthritis.Elife. 2020 May 22;9:e57656. doi: 10.7554/eLife.57656. Elife. 2020. PMID: 32441256 Free PMC article.
-
Identification of WB4101, an α1-Adrenoceptor Antagonist, as a Sodium Channel Blocker.Mol Pharmacol. 2018 Aug;94(2):896-906. doi: 10.1124/mol.117.111252. Epub 2018 Jun 8. Mol Pharmacol. 2018. PMID: 29884692
-
Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models.Neurosci Lett. 2021 May 14;753:135844. doi: 10.1016/j.neulet.2021.135844. Epub 2021 Mar 26. Neurosci Lett. 2021. PMID: 33775738 Review.
-
Scorpion Toxins Targeting Voltage-gated Sodium Channels Associated with Pain.Curr Pharm Biotechnol. 2018;19(11):848-855. doi: 10.2174/1389201019666181105160744. Curr Pharm Biotechnol. 2018. PMID: 30398114 Review.
Cited by
-
New Insights on the Therapeutic Potential of Runt-Related Transcription Factor 2 for Osteoarthritis: Evidence from Mendelian Randomization.Rheumatol Ther. 2024 Aug;11(4):1001-1009. doi: 10.1007/s40744-024-00682-1. Epub 2024 Jun 14. Rheumatol Ther. 2024. PMID: 38874858 Free PMC article.
-
How do small quantities of cartilage sodium channels play a significant role in osteoarthritis?Clin Transl Med. 2024 Mar;14(3):e1634. doi: 10.1002/ctm2.1634. Clin Transl Med. 2024. PMID: 38530147 Free PMC article. No abstract available.
-
Hnrnpk protects against osteoarthritis through targeting WWC1 mRNA and inhibiting Hippo signaling pathway.Mol Ther. 2024 May 1;32(5):1461-1478. doi: 10.1016/j.ymthe.2024.02.027. Epub 2024 Feb 27. Mol Ther. 2024. PMID: 38414246
-
Sodium channel Nav1.7 regulates chondrocyte biology and OA progression.Nat Rev Rheumatol. 2024 Mar;20(3):137. doi: 10.1038/s41584-024-01090-z. Nat Rev Rheumatol. 2024. PMID: 38326427 No abstract available.
References
-
- Sugimoto T, Yoshino M, Nagao M, Ishii S, Yabu H. Voltage-gated ionic channels in cultured rabbit articular chondrocytes. Comp. Biochem. Physiol. C. 1996;115:223–232. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous